title: New treatment options for patients with metastatic prostate cancer.
abstract: Prostate cancer is one of the most common cancers in men. When metastasised (40% of patients), classic anti-androgen therapy is the first-line treatment. Usually, this treatment becomes ineffective when castration-resistant prostate cancer (CRPC) develops. Thus far, docetaxel was the only chemotherapeutic option that has shown to be able to extend overall survival and improve quality of life in these patients. Recently, cabazitaxel and abiraterone have shown significant survival benefits for patients progressive on or after docetaxel treatment, as did enzalutamide and radium-223. In North America, immune therapy (sipuleucel-T) became available for a subgroup of CRPC patients. These new treatment options will change the treatment paradigm of patients with metastatic castration resistant prostate cancer. A multidisciplinary approach by both medical oncologists and urologists seems mandatory.
authors: Department of Internal Medicine, Sint Lucas Andreas Hospital, Amsterdam, the Netherlands. l.snoeks@vumc.nl
authors: L L
authors: LL
authors: Snoeks
authors: A C
authors: AC
authors: Ogilvie
authors: E P
authors: EP
authors: van Haarst
authors: C E H
authors: CE
authors: Siegert
mesh_terms: D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D011868:Radioisotopes; D043823:Taxoids; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; C552428:cabazitaxel; C511774:sipuleucel-T; C540278:enzalutamide; D000069501:Abiraterone Acetate; C581106:radium Ra 223 dichloride; D011883:Radium